【摘要】 目的 探讨高压氧联合药物治疗突发性耳聋（sudden deafness， SD）的疗效。 方法 2008年2月-2010年7月，对174例SD患者采用高压氧（治疗压力0.2 MPa）及配合扩血管、营养神经等药物进行治疗，并观察其疗效。 结果 高压氧联合药物治疗SD总有效率为85.7％，SD的发病就诊时间是影响预后的主要因素，发病就诊时间≤7 d时，治疗有效率可达95.6%；≥15 d时，疗效明显降低。 结论 高压氧联合药物治疗SD疗效确切，且高压氧治疗越早疗效越好。 【Abstract】 Objective To observe the therapeutic effect of hyperbaric oxygen combined with medical treatment on sudden deafness. Methods Between February 2008 and July 2010, 174 patients with sudden deafness were treated by a combined therapy, including hyperbaric oxygen and medicals. The therapeutic effect was analyzed. Results The total effective rate was 85.7％. The simultaneous phenomenon such as vertigo and vomiting and onset-diagnosis duration were the two major factors affecting the prognosis. When the onset-diagnosis duration was ≤7 days, the effective rate reached 95.6%; when the onset-diagnosis duration was≥15 days, the therapeutic effect decreased significantly. Conclusion Hyperbaric oxygen combined with medical treatment is effective for sudden deafness, and the hyperbaric oxygen treatment should be performed as earlier as possible.
Objectives To investigate the correlation between blood total cholesterol (TC) and prognosis of idiopathic sudden sensorineural hearing loss (ISSNHL) and to provide references for clinical treatment and prognosis assessment. Methods We included 232 ISSNHL patients with total deafness in Wenzhou Central Hospital from June 2015 to March 2017 using a prospective cohort design. Recording information including age, gender, hypertension, diabetes mellitus, vertigo, level of blood total cholesterol (TC), level of triglyceride (TG), level of low-density lipoprotein (LDL-C) and LDL/HDL ratio (LDL-C/HDL-C) were collected. Correlation between the prognosis of ISSNHL and blood total cholesterol were analyzed by univariable and multivariable logistic regression analysis. Results The clinical effective rate of patients with TC ranging from 5.2 mmol/L to 6.2 mmol/L was higher than that of patients with TC lower than 5.2 mmol/L (univariable: RR=6.49, 95%CI 3.16 to 13.30, P<0.001; multivariable-adjusted covariates: RR=6.15, 95%CI 2.66 to 14.3,P<0.001) with significant difference. No significant difference was found between patients with TC lower than 5.2 mmol/L and patients with TC higher than 6.2 mmol/L (univariable: RR=1.02, 95%CI 0.52 to 2.00,P=0.960; multivariable-adjusted covariates: RR=1.61, 95%CI 0.55 to 4.73, P=0.386). Gender-specific analysis showed for both male and female groups, the effective rates of patients with TC ranging from 5.2 mmol/L to 6.2 mmol/L were significantly higher than those of patients with TC lower than 5.2 mmol/L. There was no significant difference between patients with TC lower than 5.2 mmol/L and patients with TC higher than 6.2 mmol/L (P>0.05) in either male group or female group. Conclusion The current study suggests that patients with levels of TC ranging from 5.2 mmol/L to 6.2 mmol/L predicts the best prognosis.
The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) published the first clinical practice guideline for sudden sensorineural hearing loss in 2012 and updated it in 2019. The guideline, which includes 13 expert consensus recommendations and treatment protocols, advocates medication (glucocorticoids are the sole optional medicine) and hyperbaric oxygen therapy. In order to provide references for the formulation of the guidelines for sudden sensorineural hearing loss that are more suitable for our national conditions, this article interprets the treatment regimens of the guideline.